Unlike traditional drug discovery efforts that have focused exclusively on the human side of the equation, Second Genome is working on therapeutic product breakthroughs by focusing on how the microbiota interacts with itself and with its human host to impact health and disease.
Second Genome's proprietary Microbiome Discovery Platform uniquely addresses current limitations in target discovery and validation by integrating world-class microbiome science with human disease biology.
Second Genome is leveraging microbiome science to develop novel therapeutics in clinical indications with large unmet needs. With the intersect between the microbiome and human health growing increasingly important in disease area research, Second Genome has focused on two key disease areas that have been tightly linked to microbial activity.
Our world-class multi-disciplinary team has completed over 300 microbiome studies across industry, government, academia, nutrition companies, and pharma. Expert-built and validated bioinformatics generate the most insightful microbiome insights. These insights are the foundation of our microbiome drug discovery platform.